The dual NDA acceptances de-risk the near-term regulatory path and create a clear catalyst calendar: relutrigine PDUFA Sep 27, 2026, ulixacaltamide PDUFA Jan 29, 2027, plus POWER1 readout in Q2 2026 and EMERALD in Q4 2026. The $1.4B cash runway into 2028 eliminates financing risk. Traders should watch for POWER1 topline results (likely within weeks) as the next major catalyst — a positive readout would validate vormatrigine's broad epilepsy potential and likely drive further upside.
Price Chart
Executive Summary
Praxis Precision Medicines reported Q1 2026 EPS of -$3.20 (GAAP), a 2.7% beat vs consensus of -$3.68, but the headline is the FDA acceptance of NDAs for ulixacaltamide (PDUFA Jan 29, 2027) and relutrigine (priority review, PDUFA Sep 27, 2026), positioning for two U.S. launches within eight months. The company also reported a 77% placebo-adjusted seizure reduction for elsunersen in early-seizure-onset SCN2A-DEE and maintains a $1.4B cash runway into 2028, funding multiple upcoming catalysts including POWER1 (FOS) topline in Q2 2026 and EMERALD (broad DEEs) in Q4 2026.
Key Financial Metrics
Key Facts
- FDA accepted NDA for ulixacaltamide in Essential Tremor with PDUFA Jan 29, 2027
- FDA accepted relutrigine NDA with priority review for SCN2A/SCN8A DEEs, PDUFA Sep 27, 2026
- Elsunersen showed 77% placebo-adjusted seizure reduction in EMBRAVE Part A (p=0.015)
- Cash and investments $1.4B as of March 31, 2026, up from $926.1M at Dec 31, 2025
- Net loss $92.6M in Q1 2026 vs $69.3M in Q1 2025, driven by increased R&D and G&A spend
- EPS of -$3.20 beat consensus of -$3.68 (2.7% beat)
- POWER1 (vormatrigine) topline results expected Q2 2026; EMERALD (relutrigine) topline Q4 2026
- Commercial organization build underway for both ulixacaltamide and relutrigine launches
Financial Impact
EPS beat of $0.48 vs consensus; cash position increased by $473.9M from follow-on offering
Risk Factors
- Regulatory risk: FDA could issue CRLs for either NDA despite Breakthrough Therapy designations
- Clinical risk: POWER1 (vormatrigine) or EMERALD (relutrigine) could miss endpoints
- Commercial execution risk: launching two drugs simultaneously in 2027 requires significant infrastructure
- Dilution risk: company may need additional capital if launches are delayed or cash burn accelerates
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3289917 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 29, 2026 13w ago | 8-K | $334.79 $282.12 | ▲ +15.73% | ▲ +18.55% | $292.66 (+12.58%) |
Jun 11, 2026 16w ago | Institutional Cluster | $247.98 $351.81 | ▲ +41.87% | ▲ +37.47% | $292.66 (+18.02%) |
Jun 2, 2026 17w ago | Press Release | $278.93 $367.85 | ▲ +31.88% | ▲ +29.38% | $292.66 (+4.92%) |
May 7, 2026 21w ago | Press Release | $333.28 $305.51 | ▼ −8.33% | ▼ −12.17% | $292.66 (−12.19%) |
May 4, 2026 21w ago | Press Release | $333.30 $307.75 | ▼ −7.67% | ▼ −10.41% | $292.66 (−12.19%) |
Apr 14, 2026 24w ago | Press Release | $343.60 $333.12 | ▼ −3.05% | ▼ −11.57% | $292.66 (−14.83%) |
Apr 6, 2026 25w ago | Press Release | $310.11 $319.60 | ▲ +3.06% | ▼ −10.41% | $292.66 (−5.63%) |
Mar 30, 2026 26w ago | Press Release | $322.19 $327.79 | ▲ +1.74% | ▼ −10.64% | $292.66 (−9.17%) |
Feb 28, 2026 30w ago | Institutional Cluster | $330.59 $350.60 | ▲ +6.05% | ▼ −3.27% | $292.66 (−11.47%) |
Feb 28, 2026 30w ago | Institutional Cluster | $330.59 $350.60 | ▲ +6.05% | ▼ −3.27% | $292.66 (−11.47%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access